Latest Meningococcal vaccine Stories
Funds to be used for surveillance of meningococcal disease in Latin America and the Caribbean Region WASHINGTON, March 12 /PRNewswire-USNewswire/ -- The Pan American Health and Education Foundation (PAHEF), a not-for-profit organization in the United States, has announced the receipt of a $1,236,672 million grant from sanofi pasteur, the vaccines division of the sanofi-aventis Group.
- NBA All-Star Grant Hill and Three-Time WNBA MVP Lisa Leslie Urge Teens to Stay in the Game and Get Vaccinated - NEW YORK, Feb.
National Meningitis Association Urges Parents to Protect Their Preteens and Teens through Vaccination MARIETTA, Ga., Jan.
One-fifth of the standard dose of a commonly used meningitis vaccine may be as effective as using the full dose, researchers in Norway said. Researchers at the Norwegian Institute of Public Health and colleagues at Epicentre -- the research arm of Doctors Without Borders/Medecins Sans Frontieres -- and Mbarara University of Science and Technology in Uganda said the finding should allow scarce vaccine resources to be stretched further, especially during epidemics in Africa. In 2004, a...
One fifth of the standard dose of a commonly used meningitis vaccine may be as effective as using the full dose. This new finding should allow scarce vaccine resources to be stretched further, especially during epidemics in Africa.In a study initiated by the Norwegian Institute of Public Health, together with Epicentre (the research arm of Doctors Without Borders/M©decins Sans Frontires), and Mbarara University of Science and Technology in Uganda, immune responses in patients receiving...
Researchers said on Tuesday, that giving just one-fifth the dose of a commonly used meningitis vaccine, may be as effective as using the full dose.
Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, a French pharmaceutical group, has announced that it is the first international vaccine company to enter the Japanese pediatric vaccine market with ActHIB vaccine.
Reportlinker.com announces that a new market research report related to the Infectious diseases industry is available in its catalogue.
SWIFTWATER, Pa. and LYON, France, June 23 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S.
New Phase III data for Menveo(R) (MenACWY-CRM) show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to Menactra(R).